Parenteral Drugs (India) (NSE:PDPL) ROC %: -8.22% (As of Mar. 2022)

What is Parenteral Drugs (India) ROC %?

Parenteral Drugs (India) NSE:PDPL 4 ROC % is -8.22% as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Parenteral Drugs (India)'s annualized return on capital (ROC %) for the quarter that ended in Mar. 2022 was -8.22%.

As of today (2026-06-26), Parenteral Drugs (India)'s WACC % is 0.00%. Parenteral Drugs (India)'s ROC % is 0.00% (calculated using TTM income statement data). Parenteral Drugs (India) earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Parenteral Drugs (India) (NSE:PDPL) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Parenteral Drugs (India)'s WACC % is 0.00%. Parenteral Drugs (India)'s ROC % is 0.00% (calculated using TTM income statement data). Parenteral Drugs (India) earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Parenteral Drugs (India) ROC % Related Terms

Parenteral Drugs (India) ROC % Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) ROC % Chart

Parenteral Drugs (India) Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

ROC %

Get a 7-Day Free Trial

-1.66

-5.30

-1.80

-1.47

-2.38

Parenteral Drugs (India) Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
ROC %	Get a 7-Day Free Trial															-0.17	-1.33	-1.38	-1.37	-8.22

4GF Score

Parenteral Drugs (India) Ltd NSE:PDPL

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Parenteral Drugs (India) ROC % Calculation

Parenteral Drugs (India)'s annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2022 is calculated as:

	ROC % (A: Mar. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Mar. 2021 )	+	Invested Capital (A: Mar. 2022 ))	/ count )
=	-551.621 * ( 1 - 30.02% )	/	( (16359.569	+	16081.379)	/ 2 )
=	-386.0243758	/	16220.474
=	-2.38 %

where

	Invested Capital		(A: Mar. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5682.036	-	78.127	-	( 0.57	-	max(0, 11436.389	-	680.729	+	0.57	))
=	16359.569

	Invested Capital		(A: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4842.338	-	97.978	-	( 0.001	-	max(0, 12008.375	-	671.356	+	0.001	))
=	16081.379

Parenteral Drugs (India)'s annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2022 is calculated as:

	ROC % (Q: Mar. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2021 )	+	Invested Capital (Q: Mar. 2022 ))	/ count )
=	-1321.556 * ( 1 - 0% )	/	( (0	+	16081.379)	/ 1 )
=	-1321.556	/	16081.379
=	-8.22 %

where

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4842.338	-	97.978	-	( 0.001	-	max(0, 12008.375	-	671.356	+	0.001	))
=	16081.379

Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -8.22% mean?

Parenteral Drugs (India) (NSE:PDPL) has a ROC % of -8.22% as of Mar. 2022. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Parenteral Drugs (India) and its competitors.

Is Parenteral Drugs (India)'s ROC % too high?

Parenteral Drugs (India)'s current ROC % is -8.22%. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.

How does Parenteral Drugs (India)'s ROC % compare to ZTS and CTLT?

Parenteral Drugs (India)'s ROC % of -8.22% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Drug Manufacturers company?

The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Parenteral Drugs (India) and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parenteral Drugs (India)'s current ROC % is -8.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Parenteral Drugs (India) stock overvalued right now?

Parenteral Drugs (India) (NSE:PDPL) has a current ROC % of -8.22%. The current ROC % is -8.22%. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current ROC % is -8.22% as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:524768 BOM:524400 BOM:540359 BOM:524590 BOM:531541 BOM:531210 BOM:524572 BOM:523620 BOM:539938 BOM:524632 XTER:MRK ZTS TSE:4502 NSE:SUNPHARMA CTLT TSE:4507 SHSE:600196 SZSE:000538 VTRS NSE:DIVISLAB

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001

Website http://www.pdindia.com

Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.

4GF Score

Get the complete analysis for NSE:PDPL

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90

Price

View NSE:PDPL Analysis

See ROC % data for all stocks →